ASTRAZENECA DL-,25 SP.ADR
ASTRAZENECA DL-,25 SP.ADR/ US0463531089 /
ZEGA
2024-03-28 8:16:14 AM
|
Chg.
+2.00
|
Volume |
Bid9:35:27 PM |
Ask9:35:27 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
63.00EUR
|
+3.28%
|
0 Turnover: 0.00 |
-Bid Size: - |
-Ask Size: - |
194.05 bill.EUR |
- |
- |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
CEO |
Pascal Soriot |
Management board |
Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Menelas (Mene) Pangalos, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
Supervisory board |
Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg |
Company calendar
CW 15 | 2024-04-11
General Shareholder Meeting
|
CW 17 | 2024-04-25
Interim Report 1st Quarter/3 Months
|
CW 30 | 2024-07-25
Interim Report 2nd Quarter/6 Months
|
CW 32 | 2024-08-08
Ex-Dividend
|
CW 32 | 2024-08-09
Record Date
|